BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Leucovorin 50 mg/5 mL 200 mg/20 mL 1000 mg/100 mL (GMP) (F)(PFL) no preservative [1]	N/A	10 mg/mL [1]	50 mg: discard unused portion [1,2] 200 mg,1000 mg: 8 h F [1,2]	syringe	8 h RT [1,2]	
				0.05-10 mg/mL NS, D5W, Ringer's, LR, D10W, D5-NS [1,2] 50-250 mL†	**NS**, D5W, LR, Ringer's: 24 h RT [1] D10W, D5-NS: 8 h RT [1]	
Leucovorin 50 mg/5 mL 500 mg/50 mL (Pfizer/Hospira) (F)(PFL) no preservative [3]	N/A	10 mg/mL [3]	8 h [3]	syringe	8 h RT [3]	
				0.05–10 mg/mL **NS**, D5W, LR, Ringer's, D10W, D5NS [3] 50-250 mL†	**NS**, D5W, LR, Ringer's: 24 h RT [3] D10W, D5NS: 8 h RT [3]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Leucovorin 50 mg/5 mL 500 mg/50 mL (Teva) (F)(PFL) no preservative [4]	N/A	10 mg/mL [5]	discard unused portion [5]	syringe	8 h [6,7]	
				0.4 - 4.8 mg/mL **NS**, D5W [8] 50-250 mL†	72 h **F**, RT [8]	
				0.06 - 0.4 mg/mL **NS**, D5W [4] 50-250 mL†	**NS**: 24 h RT [4] D5W: 12 h RT [4]	
				0.06 - 1 mg/mL Ringer's, Lactated Ringer's, D10W, D10-NS [4]	Ringer's, LR: 24 h RT [4] D10W: 12 h RT [4] D10NS: 6 h RT [4]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Lurbinectedin 4 mg (Jazz) (F) no preservative [9]	8 mL SWI [9]	0.5 mg/mL [9]	12 h **F**, RT [9,10]	100-250 mL **NS**, D5W [9]	complete administration within 24 h **F**, RT [9]	- larger infusion volume is recommended for peripheral line [9] - do not use nylon membrane filters for administration if diluted in NS [9]; BD Alaris pumps and syringe sets have polyethersulfone membrane in-line filters [11]
Lurbinectedin 4 mg (Pharma Mar) (F) no preservative [12] (SAP)	8 mL SWI [12]	0.5 mg/mL [12]	12 h **F**, RT [12,10]	100–250 mL **NS**, D5W [12]	30 h **F**, RT [12]	- larger infusion volume is recommended for peripheral line [12]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Melphalan 50 mg (Marcan) (RT)(PFL) no preservative [13]	10 mL supplied diluent [13] rapidly add diluent and immediately shake vigorously to dissolve [13] record time of reconstitution	5 mg/mL [13]	2 h RT [13] **do NOT refrigerate** [13]	0.1-0.45 mg/mL **NS** only [13]	complete administration within 50 min RT from time of initial reconstitution [13]	- will precipitate if stored in fridge [13]
Melphalan 50 mg (Taro) (RT)(PFL) no preservative [14]	10 mL supplied diluent [14] rapidly add diluent and immediately shake vigorously to dissolve [14] record time of reconstitution	5 mg/mL [14]	2 h RT [14] **do NOT refrigerate** [14]	0.1-0.45 mg/mL **NS** only [14]	complete administration within 50 min RT from time of initial reconstitution [14]	- will precipitate if stored in fridge [14]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Mesna 400 mg/4 mL 1000 mg/10 mL (Baxter) (RT) no preservative [15]	N/A	100 mg/mL [15] (use filter needle to withdraw from ampoule)	discard unused portion [15]	≥1 mg/mL **NS**, D5W, D5½-NS, LR [15-17] 100 mL†	24 h RT [15]	
Mesna 1000 mg/10 mL 5000 mg/50 mL (Baxter) (RT) preservative [15]	N/A	100 mg/mL [15]	8 d RT [15] (vial may be punctured up to 4 times) [15]	≥1 mg/mL **NS**, D5W, D5½-NS, LR [15-17] 100 mL†	24 h RT [15]	
Mesna 1000 mg/10 mL (Fresenius Kabi) (RT) preservative [18]	N/A	100 mg/mL [18]	14 d **F, R**T [18,19]	≥1 mg/mL **NS**, D5W [20] 100 mL†	48 h F, 24 h RT [18]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Methotrexate 50 mg/2 mL 500 mg/20 mL 1 g/40 mL (Accord) (RT)(PFL) no preservative [21]	N/A	25 mg/mL [21]	50mg: discard unused portion [21] 500 mg, 1 g: 8 h RT [21]	syringe	use within 8 h RT of initial puncture [21]	- for high-dose regimens (e.g., 1-12 g/m^2 as a single dose): use preservative-free methotrexate [21] - do not use for IT injection
				0.4–2 mg/mL **NS**, D5W [21] 50-500 mL†	use within 24 h RT of initial puncture [21] **(PFL)	
				high dose (e.g., 1-12 g/m^2 as a single dose): 1000 mL* NS	use within 24 h RT of initial puncture [21] **(PFL)	
Methotrexate **<u>intravitreal injection</u>** 50 mg/2 mL (Accord) (RT)(PFL) no preservative [21]	N/A	25 mg/mL [21]	discard unused portion [21]	syringe for intravitreal use	use within 4 h of initial puncture [10]	- for intravitreal use preservative-free methotrexate is preferred [22]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Methotrexate **IT Injection** Only preservative free methotrexate may be administered by the intrathecal route [23] 50 mg/2 mL (Accord) (RT)(PFL) no preservative [21]	N/A	25 mg/mL [21]	discard unused portion [21]	IT syringe qs to 6 mL with preservative free NS [24,25] diluents containing preservatives should **NOT** be used for intrathecal administration [26]	use within 4 h of initial puncture [10]	- auxiliary info [10]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer Ziploc bag [27]
Methotrexate 50 mg/2 mL 500 mg/20 mL (Accord) (RT)(PFL) preservative [21]	N/A	25 mg/mL [21]	28 d F [10,21]	syringe	10 d **F** [10,21]	- contains benzyl alcohol [21] - do NOT use for high-dose regimens (e.g., 1-12 g/m^2 as a single dose) [21] - do NOT use for IT injection [21]
				0.4–2 mg/mL **NS**, D5W [21] 50-500 mL†	24 h RT [21]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Methotrexate 50 mg/2 mL 500 mg/20 mL 1 g/40 mL 2.5 g/100 mL (Pfizer/Hospira) (RT)(PFL) no preservative [28]	N/A	25 mg/mL [28]	50mg: discard unused portion [28] 500 mg, 1 g, or 2.5 g: 8 h RT [28]	syringe	use within 8 h RT of initial puncture [28]	- for high-dose regimens (e.g., 1-12 g/m^2 as a single dose): use preservative-free methotrexate [28] - do not use for IT injection
				0.4–2 mg/mL **NS**, D5W [28] 50-500 mL†	use within 24 h RT of initial puncture [28] **(PFL)	
				high dose (e.g., 1-12 g/m^2 as a single dose): 1000 mL* NS	use within 24 h RT of initial puncture [28] **(PFL)	
Methotrexate **<u>intravitreal injection</u>** 50 mg/2 mL (Pfizer/Hospira) (RT)(PFL) no preservative [28]	N/A	25 mg/mL [28]	discard unused portion [28]	syringe for intravitreal use	use within 4 h of initial puncture [10]	- for intravitreal use preservative-free methotrexate is preferred [22]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Methotrexate **<u>IT Injection</u>** Only preservative free methotrexate may be administered by the intrathecal route [23] 50 mg/2 mL (Pfizer/Hospira) (RT)(PFL) no preservative [28]	N/A	25 mg/mL [28]	discard unused portion [28]	IT syringe qs to 6 mL with preservative free NS [24,25] diluents containing preservatives should **NOT** be used for intrathecal administration [26]	use within 4 h of initial puncture [10]	- auxiliary info [10]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer Ziploc bag [27]
Methotrexate 50 mg/2 mL 500 mg/20 mL (Pfizer/Hospira) (RT)(PFL) preservative [28]	N/A	25 mg/mL [28]	28 d F [10,28]	syringe	10 d **F** [10,28]	- contains benzyl alcohol [28] - do NOT use for high-dose regimens (e.g., 1-12 g/m^2 as a single dose) [28] - do NOT use for IT injection [28]
				0.4–2 mg/mL **NS**, D5W [28] 50-500 mL†	24 h RT [28]	
Mitomycin 20 mg (Accord) (RT)(PFL) no preservative [29]	40 mL SWI [29] shake well [29]	0.5 mg/mL [29]	12 h F, 6 h RT [10,30] **(PFL) [30]	syringe	72 h F, 6 h RT [30] **(PFL) [30]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Mitomycin <u>intravesical</u> 20 mg (Accord) (RT)(PFL) no preservative [29]	40 mL SWI [29] shake well [29]	0.5 mg/mL [29]	12 h F, 6 h RT [10,30] **(PFL) [30]	syringe	72 h F, 6 h RT [30] **(PFL) [30]	
	10 mL SWI [31] shake well [29]	2 mg/mL [31]	use immediately after preparation to prevent precipitation [32]	syringe	use immediately after preparation to prevent precipitation [32]	- may precipitate due to low solubility [32,33] - do NOT refrigerate [32]
	25 mL SWI shake well	0.8 mg/mL [34]	discard unused portion [34,2] **(PFL) [34,2]	syringe	4 days RT [34] **(PFL) [34,2]	- do NOT refrigerate [34]
	33.3 mL SWI shake well	0.6 mg/mL [34]	discard unused portion [34,2] **(PFL) [34,2]	syringe	4 days **F**, RT [34] **(PFL) [34,2]	
Mitomycin <u>intraperitoneal</u> 20 mg (Accord) (RT)(PFL) no preservative [29]	40 mL SWI [29] shake well [29]	0.5 mg/mL [29]	12 h F, 6 h RT [10,30] **(PFL) [30]	0.02-0.04 mg/mL **NS**, sodium lactate [29]	NS: 18 h F, 3 h RT [30] sodium lactate: 6 h F, 3 h RT [30]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Mitomycin 20 mg (Teva) (RT)(PFL) no preservative [35]	40 mL SWI [35] shake well [35]	0.5 mg/mL [35]	12 h F, 6 h RT [10,35] **(PFL) [35]	syringe	72 h F, 6 h RT [35] **(PFL) [35]	
Mitomycin **<u>intravesical</u>** 20 mg (Teva) (RT)(PFL) no preservative [35]	40 mL SWI [35] shake well [35]	0.5 mg/mL [35]	12 h F, 6 h RT [10,35] **(PFL) [35]	syringe	72 h F, 6 h RT [35] **(PFL) [35]	
	10 mL SWI [31] shake well [35]	2 mg/mL [31]	use immediately after preparation to prevent precipitation [32]	syringe	use immediately after preparation to prevent precipitation [32]	- may precipitate due to low solubility [32,33] - do NOT refrigerate [32]
	25 mL SWI shake well	0.8 mg/mL [34]	discard unused portion [34,2] **(PFL) [34,2]	syringe	4 days RT [34] **(PFL) [34,2]	- do NOT refrigerate [34]
	33.3 mL SWI shake well	0.6 mg/mL [34]	discard unused portion [34,2] **(PFL) [34,2]	syringe	4 days **F**, RT [34] **(PFL) [34,2]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Mitomycin **<u>intraperitoneal</u>** 20 mg (Teva) (RT)(PFL) no preservative [35]	40 mL SWI [35] shake well [35]	0.5 mg/mL [35]	12 h F, 6 h RT [10,35] **(PFL) [35]	0.02-0.04 mg/mL **NS**, sodium lactate [35]	NS: 18 h F, 6 h RT [35] sodium lactate: 6 h **F**, RT [35]	
mitoXANTRONE 20 mg/10 mL (Fresenius Kabi) (RT) no preservative [36]	N/A	2 mg/mL [36]	discard unused portion [36]	0.2-0.6 mg/mL **NS**, D5W [36] 50 mL†	24 h RT [36]	
mitoXANTRONE 20 mg/10 mL 25 mg/12.5 mL 30 mg/15 mL (Pfizer/Hospira) (RT)(PFL) no preservative [37]	N/A	2 mg/mL [37]	discard unused portion [37]	0.2-0.6 mg/mL **NS**, D5W [37] 50 mL†	72 h F, 24 h RT [37] **(PFL) [37]	
Mogamulizumab 20 mg/5 mL (Kyowa) (F)(PFL) do not shake no preservative [38]	N/A	4 mg/mL [38]	discard unused portion [38]	0.1-3 mg/mL NS 100 mL* mix by gentle inversion; do not shake [38]	24 h F [38]	- discard if cloudy, discoloured, or visible particulates are present [38] - administer with 0.2 micron in-line filter [38]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Nelarabine 250 mg/50 mL (Sandoz) (RT) no preservative [39]	N/A	5 mg/mL [39]	discard unused portion [39]	undiluted in empty PVC infusion bag or glass container [39]	8 h RT [39]	- discard if discoloured, hazy, or particulates are present [39]
Nivolumab 40 mg/4 mL 100 mg/10 mL (BMS) (F)(PFL) do not shake no preservative [40]	N/A	10 mg/mL [40]	discard unused portion [40]	1-10 mg/mL **NS**, D5W [40] 25-100 mL† mix by gentle inversion; do not shake [40] OR undiluted in empty infusion bag or glass bottle [40]	complete administration within 7 days F, including max 8 h at RT [40] **(PFL) [40] (can be in room light when at RT) [40]	- do not shake [40] - administer with 0.2 micron in-line filter [40] - may contain a few amorphous particles [40] - discard if cloudy, has pronounced colour change (should be clear to pale yellow) [40]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Nivolumab-relatlimab 240 mg-80 mg/20 mL (BMS) (F)(PFL) do not shake no preservative [41]	N/A	12 mg/mL nivolumab-4 mg/mL relatlimab	discard unused portion [41]	3-12 mg/mL nivolumab 50-100 mL† **NS**, D5W [41] mix by gentle inversion; do not shake [41] (OR undiluted in empty infusion bag or glass bottle [41])	complete administration within 24 h F, 8 h RT [41] **(PFL) [41] (can be in room light when at RT) [41]	- do not shake [41] - administer with a 0.2 micron in-line filter [41] - discard if cloudy, discoloured or contains particulate [41] - may contain a few translucent-to-white particles [41]
oBINutuzumab 1000 mg/40 mL (Roche) (F)(PFL)** do not shake no preservative [42]	N/A	25 mg/mL [42]	discard unused portion [43]	**NS** 100 mg: 100 mL [42] 900 mg: 250 mL [42] 1000 mg: 250 mL [42]	24 h **F**, 48 h RT [42,44]	-once removed from the fridge, diluted product is stable for an additional 48 h RT [42,44] - do NOT shake [42] - do NOT use dextrose containing solutions [42]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Octreotide 50 mcg/1 mL 100 mcg/1 mL 500 mcg/1 mL (Omega) (F)(PFL) no preservative [45]	N/A	50 mcg/mL [45]	discard unused portion [45]	NS [45] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h [45]	24 h RT [45]	
		100 mcg/mL [45]				
		500 mcg/mL [45]				
Octreotide multidose vial: 1000 mcg/5 mL (Omega) (F)(PFL) preservative [45]	N/A	200 mcg/mL [45]	15 d F [45]	NS [45] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h [45]	24 h RT [45]	
Octreotide (SANDOSTATIN®) 50 mcg/1 mL 100 mcg/1 mL 500 mcg/1 mL (Novartis) (F)(PFL) no preservative [46]	N/A	50 mcg/mL [46]	discard unused portion [46]	NS [46] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h [46]	24 h RT [46]	
		100 mcg/mL [46]				
		500 mcg/mL [46]				

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Octreotide (SANDOSTATIN®) multi-dose vial: 1000 mcg/5 mL (Novartis) (F)(PFL) preservative [46]	N/A	200 mcg/mL [46]	14 d **F**, RT [46]	NS [46] volume adjusted to ensure a continuous infusion of octreotide at 25 mcg/h [46]	24 h RT [46]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Octreotide (SANDOSTATIN LAR®) (long acting) 10 mg 20 mg 30 mg (Novartis) (F)(PFL) no preservative [46]	2 mL supplied diluent [46] add diluent: gently run diluent down sides of vial [46] do NOT disturb for 2–5 min; then swirl moderately [46] record time of reconstitution	10 mg: 5 mg/mL [46] 20 mg: 10 mg/mL [46] 30 mg: 15 mg/mL [46]	discard unused portion [46]	syringe (for deep intragluteal administration only) [46]	use within 4 h of initial reconstitution [46,10]	- do NOT shake [46]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Octreotide suspension (long acting) 10 mg 20 mg 30 mg (Teva) (F)(PFL) no preservative [47]	2 mL supplied diluent let stand at RT for 30 min prior to reconstitution [47] add supplied diluent [47] let vial stand for 5 min after adding diluent to saturate powder [47] shake moderately in horizontal direction for ≥30 sec to create suspension [47] record time of reconstitution	10 mg: 5 mg/mL [47] 20 mg: 10 mg/mL [47] 30 mg: 15 mg/mL [47]	discard unused portion [47]	syringe (for deep intragluteal administration only) [47]	use within 4 h of initial reconstitution [47,10]	- gently shake to resuspend before administration [47] - delay in administration may result in sedimentation [47]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 200 mg/40 mL (Dr. Reddy's) (RT)(PFL) no preservative [48]	N/A	5 mg/mL [48]	discard unused portion [48]	0.2-0.7 mg/mL D5W [48] 100-500 mL† do **NOT** use NS or other chloride-containing solution [48] do **NOT** use aluminum-containing needle and syringe [48]	0.2-2 mg/mL: 48 h F, 24 h RT [48]	- do **NOT** use aluminum-containing needle, syringe, or tubing [48]
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 200 mg/40 mL (Pfizer/Hospira) (RT) no preservative [49]	N/A	5 mg/mL [49]	discard unused portion [49]	0.2-0.7 mg/mL D5W [49] 100-500 mL† do **NOT** use NS or other chloride-containing solutions [49] do **NOT** use aluminum-containing needle and syringe [49]	**0.2-0.4 mg/mL:** 24 h RT [49] or 5 d F plus an additional 8 h RT [50] **0.5–2 mg/mL:** 24 h RT [49] or 10 d F, plus an additional 8 h RT [50,10] **(PFL) when stored in F [50]	- do **NOT** use aluminum-containing needle, syringe, tubing [49]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 150 mg/30 mL 200 mg/40 mL (Sandoz) (RT)(PFL) no preservative [51]	N/A	5 mg/mL [51]	12 h **F**, RT [52,10]	0.2-0.7 mg/mL D5W [51] 100-500 mL† do **NOT** use NS or other chloride-containing solution [51] do **NOT** use aluminum-containing needle and syringe [51]	0.2-2 mg/mL: 48 h F, 24 h RT [51]	- do **NOT** use aluminum-containing needle, syringe, tubing [51]
Oxaliplatin 50 mg/10 mL 100 mg/20 mL 200 mg/40 mL (Teva) (RT)(PFL) no preservative [53]	N/A	5 mg/mL [53]	discard unused portion [53]	0.2-0.7 mg/mL D5W [53] 100-500 mL† do **NOT** use NS or other chloride-containing solution [53] do **NOT** use aluminum-containing needle and syringe [53]	0.2-2 mg/mL: 48 h F, 24 h RT [53]	- do **NOT** use aluminum-containing needle, syringe or tubing [53]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
PACLitaxel 30 mg/5 mL 100 mg/16.7 mL 300 mg/50 mL (Accord) (RT)(PFL) preservative [54]	N/A	6 mg/mL [54]	30 mg, 100 mg: 28 d RT [10,54] 300 mg: 24 h RT [10,54]	0.3-1.2 mg/mL **NS**, D5W, D5NS, D5LR [54] 50-500 mL†	complete administration within 27 h RT [54]	- use non-DEHP bag and tubing [54] - administer with 0.2 micron in-line filter [54] - avoid excessive shaking [54]
				0.1 mg/mL **NS** [55]	44 h **F**, RT [55]	
PACLitaxel 30 mg/5 mL 100 mg/16.7 mL 300 mg/50 mL (Biolyse) (RT) preservative [56]	N/A	6 mg/mL [56]	28 d RT [57]	0.3-1.2 mg/mL **NS,** D5W [56] 50-500 mL†	complete administration within 27 h RT [58,59]	- use non-DEHP bag and tubing [56] - administer with 0.2 micron in-line filter [56]
				0.1 mg/mL **NS** [55]	44 h **F**, RT [55]	
				0.012-0.12 mg/mL **NS** [60]	16 h RT [58]	
				devices with spikes (e.g., chemo dispensing pins) **may be used** with vials [61]		

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Paclitaxel 30 mg/5 mL 100 mg/16.7 mL 300 mg/50 mL (Sandoz) (RT)(PFL) preservative [62]	N/A	6 mg/mL [62]	30 mg, 100 mg: 28 d RT [62,10] 300 mg: 24 h RT [62,10]	0.3-1.2 mg/mL **NS**, D5W, D5NS [62] 50-500 mL†*	complete administration within 27 h RT [62]	- use non-DEHP bag and tubing [62] - administer with 0.2 micron inline filter [62] - avoid excessive shaking
				0.1 mg/mL **NS** [55]	44 h **F**, RT [55]	
PACLitaxel, nanoparticle, albumin-bound (NAB) 100 mg (Celgene) (RT)(PFL) no preservative [63]	20 mL NS [63] slowly direct diluent against side of vial (i.e., ≥1 min) during reconstitution [63] let stand for ≥5 min to wet powder [63] gently swirl or invert for ≥2 min [63]	5 mg/mL [63]	use immediately (RT) or 8 h F [63] **(PFL) [63]	undiluted in empty PVC, non-PVC, or non-DEHP infusion bag [63]	48 h F plus an additional 8 h RT [64]	- each vial contains 900 mg human albumin [63] - to prevent foaming, do NOT inject NS directly onto the powder [63] - some settling may occur; use mild agitation to resuspend [63] - administer with 15 micron filter ONLY [63] (NOTE: filters with pore size less than 15 microns may cause filter blockage) [65]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
PACLitaxel, nanoparticle, albumin-bound (NAB) 100 mg (Panacea/Apo) (RT)(PFL) no preservative [66]	20 mL NS [66] slowly direct diluent against side of vial (i.e., ≥1 min) during reconstitution [66] let stand for ≥5 min to wet powder [66] gently swirl or invert for ≥2 min [66] (if foaming occurs, let stand for ≥15 min) [66]	5 mg/mL [66]	use immediately (RT) or 8 h F [66] **(PFL) [66]	undiluted in empty PVC, non-PVC, or non-DEHP infusion bag [66]	56 h F plus an additional 4 h RT [67]	- each vial contains 900 mg human albumin [66] - to prevent foaming, do NOT inject NS directly onto the powder [66] - some settling may occur; use gentle inversion to resuspend [66] - discard if visible particulates are present [66] - administer with 15 micron filter ONLY [66]
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Fresenius Kabi) (RT) no preservative [68]	N/A	3 mg/mL [68] 6 mg/mL [68] 9 mg/mL [68]	discard unused portion [68]	≤0.36 mg/mL [68] **NS**, D5W [68] 250 mL†	24 h RT [68]	- do **NOT** mix with calcium containing solutions (e.g., Lactated Ringer's) [68]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Hospira) (RT) no preservative [69]	N/A	3 mg/mL [69] 6 mg/mL [69] 9 mg/mL [69]	discard unused portion [69]	0.06–0.36 mg/mL **NS**, D5W [69] 250 mL†	24 h F plus an additional 24 h RT (total 48 h) [69] **(PFL) [69]	- do **NOT** mix with calcium containing solution (e.g., Lacated Ringer's) [69]
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Omega) (RT) no preservative [70]	N/A [70]	3 mg/mL [70] 6 mg/mL [70] 9 mg/mL [70]	discard unused portion [70]	0.06–0.36 mg/mL **NS**, D5W [70] 250 mL†	24 h F plus an additional 24 h RT (total 48 h) [70] **(PFL) [70]	- do **NOT** mix with calcium containing solution (e.g., Lactated Ringer's) [70]
Pamidronate 30 mg/10 mL 60 mg/10 mL 90 mg/10 mL (Pfizer) (RT) no preservative [71]	N/A	3 mg/mL [71] 6 mg/mL [71] 9 mg/mL [71]	discard unused portion [71]	0.06-0.36 mg/mL **NS**, D5W [71] 250 mL†	24 h F plus an additional 24 h RT (total 48 h) [71] **(PFL) [71]	- do **NOT** mix with calcium containing solution (e.g., Lactated Ringer's) [71]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pamidronate 30 mg/10 mL 60mg/10 mL 90 mg/10 mL (Sandoz Canada) RT no preservative [72]	N/A	3 mg/mL [72] 6 mg/mL [72] 9 mg/mL [72]	discard unused portion [72,73]	**NS**; D5W [72] 250 mL†	24 h RT [72]	- do **NOT** mix with calcium containing solution (e.g., Lactated Ringer's) [72]
PANitumumab 100 mg/5 mL 400 mg/20 mL (Amgen) (F)(PFL) do not shake no preservative [74]	N/A	20 mg/mL [74]	discard unused portion [74]	1-10mg/mL NS [74] 100 mL†	24 h F, 6 h RT [74-77]	- administer with 0.2 micron in-line filter [74] - solution may contain particulates which do not affect product quality [74] - do not administer if discoloured [74]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pegaspargase (pegylated asparaginase *E. coli*) 3750 units/5 mL (Servier) (F)(PFL) do not shake no preservative [78]	N/A	750 units/mL [78]	discard unused portion [78]	IM [78]: max volume: 2 mL in children and adolescents; 3 mL in adults if volume greater than above, use multiple sites [78]	syringe: use within 4 h of vial puncture [78,2]	- do NOT shake [78]
				IV [78]: 100 mL **NS**, D5W	bag: use within 4 h of vial puncture [78,2]	
Pembrolizumab 100 mg/4 mL (Merck) (F)(PFL) do not shake no preservatives [79]	N/A	25 mg/mL [79]	discard unused portion [79,2]	1-10 mg/mL **NS**, D5W [79] 50 mL* mix by gentle inversion [79]	complete administration within 96 h F, 6 h RT [79]	- administer with 0.2 micron in-line filter [79] - bring vials and diluted solutions to RT prior to use [79] - vials contain 0.25 mL overfill [79]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pemetrexed 100 mg 500 mg (Accord) (RT) no preservative [80]	100 mg: 4.2 mL NS [80] 500 mg: 20 mL NS [80]	25 mg/mL [80]	12 h **F**, RT [10,80]	100 mL NS [80]	24 h **F**, RT [80]	- do **NOT** mix with calcium containing solution (e.g., Ringer's) [80]
Pemetrexed 100 mg/4 mL 500 mg/20 mL 850 mg/34 mL 1000 mg/40 mL (Accord) (RT)(PFL) no preservative [81]	N/A	25 mg/mL [81]	discard unused portion [81]	100 mL NS [81]	24 h F [81]	- do **NOT** mix with calcium containing solution (e.g., Ringer's) [81]
Pemetrexed 100 mg 500 mg (Dr. Reddy's) (RT) no preservative [82]	100 mg: 4.2 mL NS [82] 500 mg: 20 mL NS [82]	25 mg/mL [82]	12 h **F**, RT [10,83-85]	100 mL NS [82]	24 h **F**, RT [85,83,84]	- do **NOT** mix with calcium containing solution (e.g., Ringer's) [82]
Pemetrexed 100 mg 500 mg (Lilly) (RT) no preservative [86]	100 mg: 4.2 mL NS [86] 500 mg: 20 mL NS [86]	25 mg/mL [86]	12 h **F** [10,86]	100 mL NS [86]	24 h **F** [86]	- do **NOT** mix with calcium containing solution (e.g., Ringer's) [86]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Pemetrexed 100 mg 500 mg 1000 mg (Taro) (RT) no preservative [87]	100 mg: 4.2 mL NS [87] 500 mg: 20 mL NS [87] 1000 mg: 40 mL NS [87]	25 mg/mL [87]	12 h F [10,87]	100 mL NS [87]	24 h F [87]	- do **NOT** mix with calcium containing solution (e.g., Ringer's) [87]
Pentostatin 10 mg (Hospira/Pfizer) (F) no preservative [88]	5 mL SWI [88]	2 mg/mL [88]	8 h RT [88]	0.18-0.33 mg/mL [88] 25-50 mL **NS**, D5W [88]	8 h RT [88]	
PERTuzumab 420 mg/14 mL (Roche) (F)(PFL) no preservative [89]	N/A	30 mg/mL [89] do NOT shake [89]	discard unused portion [89,43]	250 mL **NS** only [89] mix by gentle inversion to avoid foaming [89]	24 h **F**, RT [89]	- do NOT use dextrose containing solutions [89]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
PERTuzumab-trastuzumab 1200 mg-600 mg/15 mL 600 mg-600 mg/10 mL (Roche) (F)(PFL) do not shake no preservative [90]	N/A	**1200 mg-600 mg** [90]**:** 80 mg/mL pertuzumab and 40 mg/mL trastuzumab **600 mg-600 mg** [90]: 60 mg/mL pertuzumab and 60 mg/mL trastuzumab	discard unused portion [90]	SC syringe [90]	10 d F, 24 h RT [90,10]	- do not shake [90] - contains recombinant human hyaluronidase [90]
Plerixafor 24 mg/1.2 mL (sanofi-aventis) (RT) no preservative [91]	N/A	20 mg/mL [91]	discard unused portion [91]	SC syringe [91]	48 h RT [92,73]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Polatuzumab vedotin 30 mg 140 mg (Hoffman-La Roche) (F)(PFL) do not shake no preservative [93]	30 mg: 1.8 mL SWI [93] 140 mg: 7.2 mL SWI [93] direct diluent against side of vial during reconstitution [93] swirl gently to mix [93]	20 mg/mL [93] (PFL)	12 h F, RT [10,93]	0.72-2.7 mg/mL **NS**, D5W, ½NS [93] (dilute to a minimum volume of 50 mL) [93] gently invert bag to mix [93]	in NS: 72 h **F**, 4 h RT [93] in D5W or ½NS: 72 h **F**, 8 h RT [93]	- do NOT shake [93] - administer with 0.2 micron in-line filter [93] -discard if discolouration or visible particulates are present [93]
Pralatrexate 20 mg/1 mL 40 mg/2 mL (Servier) (F)(PFL) no preservative [94]	N/A	20 mg/mL [94]	discard unused portion [2]	syringe [94]	24 h **F**, RT [95] **(PFL) [95]	- do NOT dilute [94]
Raltitrexed 2 mg (Pfizer) (**F**,RT)(PFL) no preservative [96]	4 mL SWI [96]	0.5 mg/mL [96]	12 h **F**, RT [10,96]	50-250 mL **NS**, D5W [96]	complete administration within 24 h **F**, RT [96]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Ramucirumab 100 mg/10 mL 500 mg/50 mL (Eli Lilly) (F)(PFL) (do not shake) no preservative [97]	N/A	10 mg/mL [97]	discard unused portion [97]	0.4–4 mg/mL NS [98,97] 250-500 mL† gently invert to mix [97] do NOT shake [97]	24 h F, 4 h RT [97]	- administer with 0.2 micron in-line filter [97] - do NOT use dextrose containing solutions [97]
riTUXimab (RITUXAN®) 100 mg/10 mL 500 mg/50 mL (Roche) (F)(PFL) no preservative [99]	N/A	10 mg/mL [99]	discard unused portion [99]	1-4 mg/mL **NS**, D5W [99] 250-500 mL†	**NS:** 10 d F plus an additional 24 h RT [99,10] **D5W:** 24 h F plus an additional 12 h RT [99]	
riTUXimab **intravitreal injection** **(RITUXAN®)** 100 mg/10 mL (Roche) (F)(PFL) no preservative [99]	N/A	10 mg/mL [99]	discard unused portion [99]	syringe for intravitreal use	use within 4 h of initial puncture [10]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
riTUXimab **<u>subcutaneous</u>** (**RITUXAN® SC**) 1400 mg/11.7 mL 1600 mg/13.4 mL (Roche) (F)(PFL) no preservative [100]	N/A	120 mg/mL [100]	discard unused portion [100]	SC syringe [100]	48 h F plus 8 h RT [100]	- contains hyaluronidase [100] - formulations are NOT interchangeable [100]
riTUXimab (**RIXIMYO®**) 100 mg/10 mL 500 mg/50 mL (Sandoz) (F)(PFL) (do NOT shake) no preservative [101]	N/A	10 mg/mL [101]	discard unused portion [101]	1-4 mg/mL **NS**, D5W [101] 250-500 mL† gently invert to mix	**NS**: 10 d F plus an additional 24 h RT [101,10] **D5W**: 24 h F plus an additional 12 h RT [101]	
riTUXimab **<u>intravitreal injection</u>** (**RIXIMYO®**) 100 mg/10 mL (Sandoz) (F)(PFL) (do NOT shake) no preservative [101]	N/A	10 mg/mL [101]	discard unused portion [101]	syringe for intravitreal use	use within 4 h of initial puncture [10]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
riTUXimab (**RUXIENCE®**) 100 mg/10 mL 500 mg/50 mL (Pfizer) (F)(PFL) no preservative [102]	N/A	10 mg/mL [102]	discard unused portion [102]	1-4 mg/mL **NS**, D5W [102] 250-500 mL† gently invert to mix	24 h F plus an additional 24 h RT [102]	
riTUXimab **intravitreal injection** (**RUXIENCE®**) 100 mg/10 mL 500 mg/50 mL (Pfizer) (F)(PFL) no preservative [102]	N/A	10 mg/mL [102]	discard unused portion [102]	syringe for intravitreal use	use within 4 h of initial puncture [10]	
riTUXimab (**TRUXIMA®**) 100 mg/10 mL 500 mg/50 mL (Teva/Celltrion) (F)(PFL) no preservative [103]	N/A	10 mg/mL [103]	discard unused portion [103]	1-4 mg/mL **NS**, D5W [103] 250-500 mL† gently invert to mix	24 h F plus an additional 12 h RT [103]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
riTUXimab **intravitreal injection** (**TRUXIMA®**) 100 mg/10 mL 500 mg/50 mL (Teva/Celltrion) (F)(PFL) no preservative [103]	N/A	10 mg/mL [103]	discard unused portion [103]	syringe for intravitreal use	use within 4 h of initial puncture [10]	
romiDEPsin 10 mg (Celgene Australia) (RT) no preservative [104]	2.2 mL supplied diluent [104] swirl to mix [104]	5 mg/mL [104]	discard unused portion [104]	500 mL NS [104]	24 h F [104]	- vials contain overfill to allow full drug recovery (drug vial contains 11 mg romidepsin; diluent vial has 2.4 mL diluent) [104] - solvent contains 80% propylene glycol and 20% anhydrous ethanol [104]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Sacituzumab govitecan 180 mg (Gilead) (F)(PFL) no preservative [105]	20 mL NS [105] bring vials to RT before reconstitution [105] slowly add diluent to vial and gently swirl; allow to dissolve for up to 15 min [105] do not shake [105]	10 mg/mL [105]	use immediately after reconstitution to prepare infusion solution [105] discard unused portion [105]	1.1-3.4 mg/mL NS [105] 100-1000 mL† slowly inject solution to bag to minimize foaming; do not shake [105]	24 h F [105], plus an additional 8 h RT including infusion time [105] **(PFL) [105]	- do not shake [105] - protect container from light during administration [105] - vials contain overfill (~20 mg per vial) [106]
Siltuximab 100 mg 400 mg (Recordati/EUSA) (F)(PFL) no preservative[107,108]	100 mg: 5.2 mL SWI[107] 400 mg: 20 mL SWI[107] bring vial to RT prior to use (~30 min)[107] gently swirl, do NOT shake[107]	20 mg/mL[107]	2 h RT[107]	250 mL D5W[107] dilute to final volume by withdrawing volume from bag equal to volume of drug to be added[107] gently mix[107]	complete administration within 6 h RT[107]	- administer with 0.2 micron in-line filter[107] - do not use if visibly opaque, discoloured, or contains particles[107]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Sirolimus, nanoparticle, albumin-bound (NAB) 100 mg (Aadi) (F)(PFL) no preservative [109] (SAP)	20 mL NS [109] slowly direct diluent against side of vial (over ≥1 min) [109] let stand for ≥5 min to wet powder [109] gently swirl or invert for ≥2 min to avoid foaming [109] if foaming/clumping occurs, let stand until foam subsides (≥15 min) [109]	5 mg/mL [109]	4 h F [110,111] **(PFL) [109]	undiluted in empty PVC or non-PVC infusion bag [109]	9 h F, followed by max 4 h RT [109] **(PFL) [109]	- each vial contains ~800-900 mg human albumin [109,112] - to prevent foaming, do NOT inject NS directly onto the powder [109] - if powder is visible after reconstitution, gently invert to resuspend powder [109] - to prevent administration of proteinaceous strands, administer with 15 micron filter ONLY [109]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Streptozocin 1g (Keocyt) (F)(PFL) no preservative [113-116] (SAP)	9.5mL **NS,** SWI, D5W [113-116]	100 mg/mL [113-116]	12 h F [114-116,10]	syringe [114-116]	48 h F [114-116,10]	
				100-500 mL **NS**, D5W, SWI [113-116]	24 h F [114-116]	
Tarlatamab 1 mg (Amgen) (F)(PFL) no preservative [117]	1.3 mL SWI do NOT use supplied IV solution stabilizer to reconstitute vials [117] direct diluent against side of vial [117] gently swirl to mix; do not shake [117]	0.9 mg/mL [117]	discard unused portion [10]	250 mL NS [117] add 13 mL supplied IV solution stabilizer to NS bag and gently mix to avoid foaming; do not shake [117] add 1.1 mL reconstituted drug to IV bag **following** addition of IV solution stabilizer [117] gently mix by inverting bag; do not shake [117]	complete administration within 7 d F, 8 h RT [117]	- **CAUTION**: two vial sizes are available; final vial concentrations are different after reconstitution - due to low extractable volume, use filtered venting needle (e.g., Chemo-Vent®) in place of CSTD for compounding [118] -vials contain overfill to allow full drug recovery [117] - discard if cloudy or has particulates [117]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Tarlatamab 10 mg (Amgen) (F)(PFL) no preservative [117]	4.4 mL SWI [117] do NOT use supplied IV solution stabilizer to reconstitute vials [117] direct diluent against side of vial [117] gently swirl to mix; do not shake [117]	2.4 mg/mL [117]	discard unused portion [10]	250 mL NS [117] add 13 mL supplied IV solution stabilizer to NS bag and gently mix to avoid foaming; do not shake [117] add 4.2 mL reconstituted drug to IV bag **following** addition of IV solution stabilizer [117] gently mix by inverting bag; do not shake [117]	complete administration within 7 d F, 8 h RT [117]	- **CAUTION**: two vial sizes are available; final vial concentrations are different after reconstitution - due to low extractable volume, use filtered venting needle (e.g., Chemo-Vent®) in place of CSTD for compounding [118] -vials contain overfill to allow full drug recovery [117] - discard if cloudy or has particulates [117]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Tebentafusp 100 mcg/0.5 mL (Immunocore/Medison) (F)(PFL) do not shake no preservative [119]	N/A	200 mcg/mL [119]	discard unused portion [119]	100 mL NS [119] Step 1: add calculated volume of human albumin 5% to provide 225-275 mcg/mL final concentration [119] to mix: invert the bag and gently rotate ≥5 times; do NOT shake bag (repeat x3) [119] Step 2: add calculated volume of drug [119] to mix: invert the bag and gently rotate ≥5 times; do NOT shake bag (repeat x3) [119]	complete administration within 24 h F, 4 h RT [119] bring to RT prior to administration [119]	- do not use CSTD or filters during **preparation** [119]; use filtered venting needle (e.g., Chemo-Vent®) for preparation - CSTD can be used for administration [120] - administer using 0.2 micron in-line filter [119] - once the bag has been removed from fridge, it must remain at RT [119]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Teclistamab 30 mg/3 mL 153 mg/1.7 mL (Janssen) (F)(PFL) do not shake no preservative [121]	N/A	30 mg [121]: 10 mg/mL (use for 2.1-52.9 mg doses)* 153 mg [121]: 90 mg/mL (use for 53-375 mg doses)* bring to RT before use (~15 min) [121] swirl gently for 10 sec to mix; do NOT shake [121]	discard unused portion [121]	SC syringe [121] if drug volume >2 mL, divide volume into separate syringes for administration [121]	20 h **F**, RT [121] if stored in fridge, bring to RT prior to administration [121]	- **CAUTION**: two concentrations are available [121] - do not use CSTD for volumes less than 1 mL [122]; use filtered venting needle (e.g., Chemo-Vent®) for preparation [123]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Temsirolimus 30 mg/1.2 mL (Pfizer/Wyeth) (F)(PFL) [124] no preservative [125]	1.8 mL supplied diluent [124]	10 mg/mL [124]	12 h RT [124,10] **(PFL) [124]	250 mL NS [124] record time of dilution [124]	complete administration within 6 h [124] mix by gentle inversion to avoid foaming [124]	- use non-DEHP bag and tubing - administer with 0.2 micron in-line filter [124]
Teniposide 50 mg/5 mL (BMS) (RT) preservative [126]	N/A	10 mg/mL [126]	discard unused portion	0.1-1 mg/mL **NS,** D5W [126] 50–500 mL*	0.1-0.4 mg/mL: 24 h RT [126] 1 mg/mL: complete administration within 4 h RT of preparation [126,127]	- do not refrigerate - use non-DEHP bag and tubing [126] - do not use if precipitates [126,127] - contains DMA*** - excessive agitation may cause precipitation [126]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Thiotepa 15 mg 100 mg (Hikma) (F, PFL) no preservative [128]	**15 mg** [128]**:** 1.5 mL SWI **100 mg** [128]**:** 10 mL SWI to remove haze, filter through 0.22 micron filter disc after reconstitution [129] record time of reconstitution	10 mg/mL [128]	8 h F [128]	0.5-1 mg/mL NS [128] ≤500 mg [128]: 500 mL >500 mg [128]: 1000 mL reconstituted solution is hypotonic and must be further diluted with NS prior to use [128]	24 h F, 4 h RT [128]	- discard if precipitates are present [128] - reconstituted solution may be used if opalescent [128] - administer with 0.2 micron in-line filter [128] - use non-PVC bag and administration set [128]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Thiotepa **IT injection** 15 mg 100mg (Hikma) (F, PFL) no preservative [128]	**15 mg** [128]**:** 1.5 mL SWI **100 mg** [128]**:** 10 mL SWI diluents containing preservatives should **NOT** be used for intrathecal administration [26] to remove haze, filter through 0.22 micron filter disc after reconstitution [129] record time of reconstitution	10 mg/mL [128]	8 h F [128]	IT syringe qs to 6 mL with preservative free NS [130] diluents containing preservatives should **NOT** be used for intrathecal administration [26]	use within 4 h of initial reconstitution [10]	- auxiliary info [131]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [131] - discard if precipitates are present [128] - reconstituted solution may be used if opalescent [128]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Thiotepa 15 mg 100 mg (SteriMax) (F, PFL) no preservative [132]	**15 mg** [132]**:** 1.5 mL SWI **100 mg** [132]**:** 10 mL SWI to remove haze, filter through 0.22 micron filter disc after reconstitution [129] record time of reconstitution	10 mg/mL [132]	8 h F [132]	0.5-1 mg/mL NS [132] ≤500 mg [132]: 500 mL >500 mg [132]: 1000 mL reconstituted solution is hypotonic and must be further diluted with NS prior to use [132]	24 h F, 4 h RT [132]	- discard if precipitates are present [132] - reconstituted solution may be used if opalescent [132] - administer with 0.2 micron in-line filter [132] - use non-PVC bag and administration set [132]

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Thiotepa **IT injection** 15 mg 100mg (SteriMax) (F, PFL) no preservative [132]	**15 mg** [132]**:** 1.5 mL SWI **100 mg** [132]**:** 10 mL SWI diluents containing preservatives should **NOT** be used for intrathecal administration [26] to remove haze, filter through 0.22 micron filter disc after reconstitution [129] record time of reconstitution	10 mg/mL [132]	8 h F [132]	IT syringe qs to 6 mL with preservative free NS [130] diluents containing preservatives should **NOT** be used for intrathecal administration [26]	use within 4 h of initial reconstitution [10]	- auxiliary info [131]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [131] - discard if precipitates are present [132] - reconstituted solution may be used if opalescent [132]
Thyrotropin alfa 1.1 mg (Genzyme) (F)(PFL) no preservative [133]	1.2 mL SWI [133] swirl gently to mix [133] do NOT shake [133]	0.9 mg/mL [133]	12 h F [10,133]	syringe [133]	24 h F [10,133]	- do not use if particulates are present [133]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Tislelizumab 100 mg/10 mL (BeiGene) (F)(PFL) (do not shake) no preservative [134] (SAP)	N/A	10 mg/mL [134]	discard unused portion [134]	2-5 mg/mL NS [134] 50 mL* mix by gentle inversion; do not shake [134]	complete administration within 20 h F, 4 h RT (max 24 h from preparation) [134] bring to RT prior to administration [134]	- discard if has visible particulates, or is discoloured or cloudy [134] - administer with 0.2 micron in-line filter [134]
Tocilizumab 80 mg/4 mL 200 mg/10 mL 400 mg/20 mL (Roche) (F)(PFL) no preservative [135]	N/A	20 mg/mL [135]	discard unused portion [135]	100 mL NS [135] dilute to final volume by withdrawing volume from bag equal to volume of drug to be added [135] gently invert to mix [135]	complete administration within 24 h **F**, RT [135] bring to RT prior to administration [135]	- to prevent foaming: slowly add drug to infusion bag and gently invert bag to mix [135]
Topotecan 4 mg/4 mL (Accord) (RT)(PFL) no preservative [136]	N/A	1 mg/mL [136]	12 h **F**, RT [10,136]	0.025-0.5 mg/mL **NS**, D5W [136] 25-50 mL†	10 d F, 4 d RT [10,136]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Topotecan **IT injection** 4 mg/4 mL (Accord) (RT)(PFL) no preservative [136]	N/A	1 mg/mL [136]	use within 4 h of initial puncture [10]	IT syringe qs to 10 mL with preservative free NS [27,137,138] diluents containing preservatives should **NOT** be used for intrathecal administration [26]	use within 4 h of initial puncture [10]	- auxiliary info [10]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [27]
Topotecan 4 mg/4 mL (Pfizer/Hospira) (F)(PFL) no preservative [139]	N/A	1 mg/mL [139]	discard unused portion [139]	0.02-0.5 mg/mL **NS**, D5W [139] 25-50 mL†	24 h **F**, RT [139]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Topotecan **IT injection** 4 mg/4 mL (Pfizer/Hospira) (F)(PFL) no preservative [139]	N/A	1 mg/mL [139]	use within 4 h of initial puncture [10]	IT syringe qs to 10 mL with preservative free NS [27,137,138] diluents containing preservatives should **NOT** be used for intrathecal administration [26]	use within 4 h of initial puncture [10]	- auxiliary info [10]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [27]
Topotecan 4 mg/4 mL (Sandoz) (F)(PFL) no preservative [140]	N/A	1 mg/mL [140]	discard unused portion [140]	0.02-0.5 mg/mL **NS**, D5W [140] 25-50 mL†	24 h F [140] **(PFL) [140]	

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Topotecan **IT injection** 4 mg/4 mL (Sandoz) (F)(PFL) no preservative [140]	N/A	1 mg/mL [140]	use within 4 h of initial puncture [10]	IT syringe qs to 10 mL with preservative free NS [27,137,138] diluents containing preservatives should **NOT** be used for intrathecal administration [26]	use within 4 h of initial puncture [10] **(PFL) [140]	- auxiliary info [10]: IT - label to include route in full (i.e., INTRATHECAL injection) attached to both syringe and outer ziplock bag [27]
Trastuzumab (HERCEPTIN®) 440 mg (Roche) (F) no preservative [141]	20 mL supplied BWI [141] swirl vial gently; allow to stand undisturbed for 5 min [141]	21 mg/mL [141]	28 d F [141]	250 mL **NS** only [141] do NOT use dextrose containing solutions [141]	24 h **F**, RT [141]	- do NOT shake [141]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Trastuzumab (HERZUMA®) 150 mg 440 mg (Teva/Celltrion) (F) no preservative [142]	150 mg: 7.2 mL SWI [142]	21 mg/mL [142]	discard unused portion [142]	250 mL **NS** only [142] do **NOT** use dextrose containing solutions [142]	24 h **F**, RT [142]	- do NOT shake [142] - supplied BWI contains benzyl alcohol [142]
	440 mg: 20 mL supplied BWI [142]		28 d F [142]			
	swirl vial gently; allow to stand undisturbed for 5 min [142]					
Trastuzumab (OGIVRI®) 150 mg 440 mg (BGP) (F) no preservative [143]	150 mg: 7.2 mL SWI [143]	21 mg/mL [143]	discard unused portion [143]	250 mL **NS** only [143] do **NOT** use dextrose containing solutions [143]	24 h **F**, RT [143]	- do NOT shake [143] - supplied BWI contains benzyl alcohol [143]
	440 mg: 20 mL supplied BWI [143]		28 d F [143]			
	swirl vial gently; allow to stand undisturbed for 5 min [143]					

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Trastuzumab (TRAZIMERA®) 150 mg 440 mg (Pfizer) (F) no preservative [144]	150 mg: 7.2 mL SWI [144]	21 mg/mL [144]	discard unused portion [144]	250 mL **NS** only [144] do **NOT** use dextrose containing solutions [144]	24 h **F**, RT [144]	- do NOT shake [144] - supplied BWI contains benzyl alcohol [144]
	440 mg: 20 mL supplied BWI [144]		28 d F [144]			
	swirl vial gently; allow to stand undisturbed for 5 min [144]					
Trastuzumab deruxtecan (ENHERTU®) 100 mg (AstraZeneca) (F)(PFL) no preservative [145]	5 mL SWI [145] swirl gently until completely dissolved [145] do NOT shake [145]	20 mg/mL [145]	12 h F [10,145] **(PFL) [145]	100 mL D5W only [145] gently invert to mix [145] do NOT shake [145] do **NOT** use sodium chloride solution [145]	complete administration within 24 h F, 4 h RT [145] **(PFL) [145]	- do not use if reconstituted solution contains visible particulates or is cloudy or discoloured [145] - protect container from light during administration [146] - administer with 0.2 micron in-line filter [145] - if stored in fridge, bring bag to RT prior to use [145]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Trastuzumab emtansine (KADCYLA®) 100 mg 160 mg (Roche) (F)(PFL) no preservative [147]	100 mg: 5 mL SWI [147] 160 mg: 8 mL SWI [147] swirl gently until completely dissolved do NOT shake [147]	20 mg/mL [147]	12 h **F** [10,148]	250 mL **NS** or ½NS only [147] do NOT shake [147] do **NOT** use dextrose containing solutions [147]	24 h F [147]	- do not use if reconstituted solution contains visible particulates or is cloudy or discolored [147] - D5W causes aggregation of the protein [147] - for infusions prepared in NS: administer with 0.2 micron in-line filter or 0.22 micron polyethersulfane (PES) filter [147] - for infusions prepared in ½NS: filter is optional for administration [147]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Tremelimumab 25 mg/1.25 mL 300 mg/15 mL (AstraZeneca) (F)(PFL) (do not shake) no preservative [149]	N/A	20 mg/mL [149]	discard unused portion [149]	0.1-10 mg/mL NS, D5W [149] 50 mL* mix by gentle inversion; do NOT shake [149]	24 h **F**, RT [149]	- administer with 0.2 micron in-line filter [149] - discard if visible particles are present [149]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Treosulfan 1 g 5 g (Medexus) (RT) no preservative [150]	1 g [150]: 20 mL NS, D5W, SWI, ½NS 5 g [150]: 100 mL NS, D5W, SWI, ½NS **pre-heat** diluent to 25-30°C (max) [151] **shake vial** to loosen powder before adding the warmed diluent [152] vigorous shaking may be required [152]; prolonged standing time may improve solubility [150]	50 mg/mL [150]	12 h RT [10,150]	undiluted in empty infusion bag [151,150]	3 d RT [150]	- do NOT refrigerate as may precipitate [150]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Treosulfan 1 g 5 g (medac) (RT) no preservative [153,154] (SAP)	1 g [153,154]: 20 mL SWI, ½NS 5 g [153,154]: 100 mL SWI, ½NS pre-heat diluent to 25-30°C (max) [153,154] shake vial carefully to loosen powder before adding the warmed diluent [153,154] gently shake while adding diluent [153,154] (takes ~2 min to reconstititute) [153,154]	50 mg/mL [153,154]	12 h RT [10,153,155]	undiluted [156] or dilute with **NS** or D5W in empty infusion bag to final concentration of 20 mg/mL [155]	4 d RT [153,155]	- compatible with polytetrafluoroethylene filters [157] - may sometimes require vigorous shaking to reconstitute [153,154] - do NOT refrigerate as may cause precipitation [153,154]
vinBLAStine 10 mg/10 mL (Pfizer) (F)(PFL) no preservative [158]	N/A	1 mg/mL [158]	discard unused portion [158,2]	25-50 mL **NS**, D5W [159]	use within 4 h of initial vial puncture [158,2]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [160,161]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
vinBLAStine 10 mg/10 mL (Teva) (F)(PFL) no preservative [162]	N/A	1 mg/mL [162]	discard unused portion [162,2]	25-50 mL **NS**, D5W [159]	use within 4 h of initial vial puncture [162,2]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [160,161]
vinCRIStine 2 mg/2 mL 5 mg/5 mL (Pfizer/Hospira) (F)(PFL) no preservative [163]	N/A	1 mg/mL [163]	8 h F, RT [163]	0.01-0.1 mg/mL **NS**, D5W [163] 50 mL†	24 h F, RT [163] **(PFL) [163]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [160,161] - for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine)

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
vinCRIStine 1 mg/1 mL 2 mg/2 mL 5 mg/5 mL (Teva) (F)(PFL) no preservative [164]	N/A	1 mg/mL [164]	8 h **F**, RT [164]	0.01-0.1 mg/mL **NS**, D5W [164] 50 mL†	24 h F, RT [164]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [160,161] - for LYEPOCHR protocol, see entry for EPOCHR (3-in-1 solution containing either etoposide or etoposide phosphate AND DOXOrubicin and vinCRIStine)
Vinorelbine 10 mg/1 mL 50 mg/5mL (Fresenius Kabi) (F)(PFL) no preservative [165]	N/A	10 mg/mL [165]	discard unused portion [165]	0.5-2.0 mg/mL **NS**, D5W, ½NS, D5-½NS, Ringer's, Ringer's Lactate [165] 50 mL†	24 h **F**, RT [165]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [160,161]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Vinorelbine 10 mg/1 mL 50 mg/5 mL (GMP) (F)(PFL) no preservative [166]	N/A	10 mg/mL [166]	discard unused portion [2]	0.5-2.0 mg/mL **NS**, D5W, ½NS, D5-½NS, Ringer's, Ringer's Lactate [166] 50 mL†	24 h **F**, RT [166]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [160,161]
Vinorelbine 10 mg/1 mL 50 mg/5 mL (Teva) (F)(PFL) no preservative [167]	N/A	10 mg/mL [167]	discard unused portion [167]	0.5–2.0 mg/mL **NS**, D5W, ½NS, D5-½NS, Ringer's, Ringer's Lactate [167] 50 mL†	24 h **F**, RT [167]	- auxiliary info: WARNING: FOR INTRAVENOUS USE ONLY – FATAL IF GIVEN BY OTHER ROUTES [160,161]
Zoledronic acid 4 mg/5 mL (Dr Reddy's) (RT) no preservative [168]	N/A	0.8 mg/mL [168]	discard unused portion [168]	100 mL **NS**, D5W [168]	complete infusion within 24 h of preparation [168] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [168]	- do **NOT** mix with calcium containing solutions (e.g., Lactated Ringer's) [168]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Zoledronic acid 4 mg/5 mL (Marcan) (RT) no preservative [169]	N/A	0.8 mg/mL [169]	discard unused portion [169]	100 mL **NS**, D5W [169]	complete infusion within 24 h of preparation [169] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [169]	- do **NOT** mix with calcium containing solutions (e.g., Lactated Ringer's) [169]
Zoledronic acid 4 mg/5 mL (MDA) (RT) no preservative [170]	N/A	0.8 mg/mL [170]	discard unused portion [170]	100 mL **NS**, D5W [170]	complete infusion within 24 h of preparation [170] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [170]	- do **NOT** mix with calcium containing solutions (e.g., Lactated Ringer's) [170]

Activation Date: 2 March 2006
Revised Date: 1 December 2024

BC CANCER CHEMOTHERAPY PREPARATION AND STABILITY CHART						
DRUG & STRENGTH (Storage Prior to Use, Manufacturer, Preservative Status)	**Reconstitute With:**	**To Give:**	**Vial Stability**	**Product (for IV bag size selection, see Notes†)**	**Product Stability**	**Special Precautions/Notes**
Zoledronic acid (ZOMETA) 4 mg/ 5 mL (Novartis) (RT) no preservative [171]	N/A	0.8 mg/mL [171]	discard unused portion [43]	100 mL **NS,** D5W [171]	complete infusion within 24 h of preparation [171] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [171]	- do NOT mix with calcium containing solutions (e.g., Lactated Ringer's) [171]
Zoledronic acid 4 mg/5 mL (Sandoz) (RT) no preservative [172]	N/A	0.8 mg/mL [172]	discard unused portion [172]	100 ml **NS**, D5W [172]	complete infusion within 24 h of preparation [172] **refrigerate** diluted product if not used immediately after preparation; bring to RT prior to use [172]	- do NOT mix with calcium containing solutions (e.g., Lactated Ringer's) [172]

* Suggested volume based on usual dose range and any concentration range of stability data
† see BC Cancer IV Bag Selection table: standardized bag sizes are provided for select Benefit Drugs with concentration-dependent stability or large drug volume
** Protect from light means minimizing exposure to direct sunlight over a *storage* period. More specific information on protection from light (eg, protecting container and tubing during *administration*) will be indicated in the Special Precautions/Notes column.
*** Contains DMA (N,N dimethylacetamide). Product may be incompatible with closed system transfer devices (CSTD) such as ChemoLock.

Centres are not to change content locally. All suggestions for change are to be forwarded to the Cancer Drug Manual editor.

Activation Date: 2 March 2006
Revised Date: 1 December 2024

Explanatory Notes:

Stability data assumes products prepared using standard aseptic technique in biological safety cabinet at low risk for contamination according to the classification outlined in USP 797. [173,174]
Vial stability**:** Stability of solution after first puncture or reconstituted solution.
Storage temperature: If information states same stability with refrigerator and room temperature storage, then fridge stability is bolded as preferred (ie, to minimize growth of micro-organisms).
Discard unused portion**:** Unused portion from single use vials should be discarded at the end of the day.
"overfill known" is stated if the manufacturer states overfill that is present is within acceptable limits.
"Complete administration within __" is stated if the manufacturer specifies that the infusion must be completed in a specific time frame following preparation, usually including entire time required for preparation (from first puncture), storage, and administration of infusion.
Nomenclature for ***in-line filters*** has been standardized to 0.2 micron filter size. For more information, refer to CDM monograph.

Abbreviations:

BWI = bacteriostatic water for injection
CIVI: ambulatory pump = Continuous Intravenous Infusion (e.g., elastomeric infusor)
CSTD = closed system transfer device
D5W = dextrose 5% in water
DMA = N,N dimethylacetamide
F = refrigerate
non-DEHP = not containing Di(2-ethylhexyl) phthalate (DEHP)
non-PVC = not containing polyvinylchloride (PVC)
NS = normal saline
PFL = protect from light
RT = room temperature
SAP **=** drug is approved for use through the Health Canada Special Access Program
SWI = sterile water for injection

References:

1. Generic Medical Partners Inc. Leucovorin calcium injection product monograph. Toronto, Ontario; 6 Marc, 2020.
2. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; December 5 , 2018.
3. Pfizer Canada Inc. Leucovorin calcium injection product monograph. Kirkland, Quebec; 21 Jun, 2018.
4. Teva Canada Limited. Leucovorin calcium injection® product monograph. Toronto, Ontario; 5 Ma, 2014.
5. Hospira Healthcare Corporation. LEUCOVORIN CALCIUM INJECTION® product monograph. Saint-Laurent, Quebec; 7 June , 2007.
6. Novopharm Limited (Teva). LEUCOVORIN CALCIUM® Injection product information package. Toronto, Ontario; undated, undated.

Activation Date: 2 March 2006
Revised Date: 1 December 2024

7. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 6 Januar , 2006.
8. Jenny Yeung. Medical Information Specialist, Teva Canada. Personal communication. 12 Apri, 2017.
9. Jazz Pharmaceuticals Canada Incorporated. ZEPZELCA® product monograph. Mississauga, Ontario; September 29, 2021.
10. BC Cancer. Provincial Pharmacy Directive Number II-20: Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; May 1 , 2022.
11. Linda Ewing.BD US Market Manager. WW Infusion Disposables. Personal communication. Fe, 2018.
12. Pharma Mar. Lurbinectedin Compassionate Use: Preparation Guide for Infusion - edition 1. Madrid, Spain; Apri, 2019.
13. Marcan Pharmaceuticals Inc. Melphalan for injection product monograph. Ottawa, ON; July 26, 2019.
14. Taro Pharmaceuticals Inc. Taro-Melphalan product monograph. Brampton, Ontario; April 5, 2019.
15. Baxter Corporation. UROMITEXAN® product monograph. Mississauga, Ontario; 6 Augus, 2013.
16. Mona Ghobros BPharm MSc. Medical Information, Baxter Corporation. Personal communication. 29 Novembe, 2018.
17. Trissel's® 2 Clinical Pharmaceutics Database (database on the Internet). Mesna. Lexi-Comp Inc.; created by Lawrence A. Trissel; Accessed 29 Novembe, 2018. Available at: http://online.lexi.com
18. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 21 Decembe, 2017.
19. BC Cancer. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer; 19 Septembe , 2007.
20. Fresenius Kabi Canada Ltd. Mesna for injection product monograph. Richmond Hill, Ontario; 30 Marc, 2015.
21. Accord Healthcare Inc. Methotrexate injection product monograph. Kirkland, Québec; October 30, 2019.
22. Maia M, Farah ME, Belfort RN, et al. Effects of intravitreal triamcinolone acetonide injection with and without preservative. Br J Ophthalmol ; 2007;91(9):1122–1124
23. Mayne Pharma Canada. Methotrexate Product Monograph. Montreal, Quebec; Decembe, 2003.
24. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer; September 1 , 2021.
25. BC Cancer Lymphoma Tumour Group. (LYIT) BC Cancer Protocol Summary for Treatment of Lymphoma using Intrathecal Methotrexate and Cytarabine. Vancouver, British Columbia: BC Cancer; April 1 , 2022.
26. Hematology/Oncology Pharmacy Association. HOPA News Clinical Pearls: Intrathecal Chemotherapy: Focus on Drugs, Dosing, and Preparation. 13(4) ed. Chicago, Illinois, USA: Hematology/Oncology Pharmacy Association; 2016.
27. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; May 1, 2019.
28. Pfizer Canada-ULC. Methotrexate injection product monograph. Kirkland, Québec; July 8, 2019.
29. Accord Healthcare Inc. Mitomycin product monograph. Kirkland, Quebec; 7 Jun, 2017.
30. Accord Healthcare Inc. Mitomycin product monograph. Kirkland, Quebec; 16 Jul, 2018.
31. Au JLS, Badalament RA, Wientjes MG, et al. Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst ; April 18, 2001;93(8):597–604
32. Jessie LS Au PharmD PhD. Professor, Ohio State University. Personal communication. 14 Ma, 2007.
33. Myers AL, Zhang Y, Kawedia JD, et al. Solubilization and stability of mitomycin C solutions prepared for intravesical administration. Drugs R D ; 2017;17:297–304
34. Beijnen JH, Van Gijn R, Underberg WJM. (Beijnen, Van Gijn, Underberg) Louwesweg 6, 1066 EC Amsterdam, Netherlands.; J.H. Beijnen, Louwesweg 6, 1066 EC Amsterdam, Netherlands. Chemical stability of the antitumor drug mitomycin C in solutions for intravesical instillation. Journal of Parenteral Science and Technology ; 1990;44(6):332–335
35. Teva Canada Limited. Mitomycin for injection® product monograph. Toronto, Ontario; 30 Jun, 2017.
36. Fresenius Kabi Canada Ltd. Mitoxantrone injection® product monograph. Richmond Hill, Ontario; 28 September , 2016.
37. Pfizer Canada Inc. Mitoxantrone injection product monograph. Kirkland, Quebec; 17 Octobe, 2018.
38. Kyowa Kirin (Distributed by Innomar Strategies). POTELIGEO® product monograph. Oakville, Ontario; July 12, 2023.
39. Sandoz Canada Inc. ATRIANCE® product monograph . Boucherville, Quebec; November 30, 2022.
40. Bristol-Myers Squibb Canada Co. OPDIVO® product monograph. Montreal, Canada; February 28, 2022.
41. Bristol-Myers Squibb Canada. OPDUALAG® product monograph. Montreal, Quebec; 13 Septembe, 2023.
42. Hoffmann-La Roche Ltd. GAZYVA® product monograph. Mississauga, Ontario; 21 December , 2015.
43. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 Septembe , 2007.
44. Anna Sivojelezova MSc. Drug Information Associate, Hoffmann-La Roche Ltd. Personal communication. 24 Apri, 2015.

45. Omega Laboratories Limited. OCTREOTIDE ACETATE solution product monograph. Montreal, Quebec; January 25, 2022.
46. Novartis Pharmaceuticals Canada Inc. SANDOSTATIN® and SANDOSTATIN® LAR® product monograph. Dorval, Quebec; April 19, 2021.
47. Teva Canada Limited. OCTREOTIDE for injectable suspension Product Monograph. Toronto, Ontario; Aug 30, 2021.
48. Dr. Reddy's Laboratories Canada Inc. Oxaliplatin injection product monograph. Mississauga, Ontario; February 8, 2022.
49. Pfizer Canada Inc. Oxaliplatin injection product monograph. Kirkland, Quebec; 31 Ma, 2017.
50. Medical Information Pfizer Canada Inc. Personal communication. 6 Jun, 2017.
51. Sandoz Canada Inc. Oxaliplatin injection product monograph. Boucherville, Quebec; 12 Augus, 2015.
52. Katryn Vosburg. Drug Information & Pharmacovigilance Specialist, Sandoz Canada Inc. Personal communication. 26 Februar, 2016.
53. Teva Canada Limited. Teva-Oxaliplatin injection® product monograph. Toronto, Ontario; 11 Septembe, 2015.
54. Accord Healthcare Inc. Paclitaxel Injection. Kirkland, Quebec; September 14, 2020.
55. Mercure C. Stability of 0.1 mg/mL of paclitaxel for injection in sodium chloride (0.9%) solution. St Catharines, Ontario: Biolyse Pharma; 2 Februar , 2007.
56. Biolyse. PACLITAXEL FOR INJECTION® product monograph. St. Catherines, Ontario; 12 Septembe, 2013.
57. Claude Mercure. Manager BPC. Personal communication. 24 Jun, 2014.
58. Zeng Z, Lazakovitch E. Study IR 120: Physical and Chemical Stability Study of Paclitaxel for Injection in 0.9 % Sodium Chloride in concentration range 0.012-0.12 mg/mL. Biolyse Pharma ; Marc, 2010
59. Biolyse. PACLITAXEL FOR INJECTION® product monograph. St. Catherines, Ontario; 2 December , 2005.
60. Xu Q, Trissel LA, Martinez JF. Pharmaceutical Analysis Laboratory, University of Texas M. D. Anderson Cancer Center, Houston 77030. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 degrees C. Am J Hosp Pharm ; Dec 15, 1994;51(24):3058–60
61. Lisa Tavano. Biolyse Pharma Corporation. Personal communication. 14 Ma, 2012.
62. Sandoz Canada Inc. Paclitaxel injection USP product monograph . Boucherville, Quebec; October 18, 2021.
63. Celgene Inc. ABRAXANE® product monograph. Mississauga, Ontario; 31 Augus, 2018.
64. Aisling Cahill. Drug Safety and Medical Information Specialist. Celgene Inc. Personal communication. April 23, 2015.
65. Celgene Europe Limited. ABRAXANE® product monograph. Uxbridge, UK; 11 Januar, 2013.
66. Panacea Biotec Pharma Limited (distributed by Apotex Inc.). Nanoparticle, albumin-bound paclitaxel product monograph. Toronto, Ontario; November 16, 2021.
67. Panacea Biotec Pharma Limited (R&D L. In-use infusion stability study report for paclitaxel powder for injectable suspension nanoparticle, albumin-bound paclitaxel (100 mg paclitaxel/vial). Toronto, Ontario; October 4, 2023.
68. Pharmaceutical Partners of Canada. Pamidronate Disodium For Injection product monograph. Richmond Hill, Ontario; 18 January , 2010.
69. Mayne Pharma (Canada) Inc. Pamidronate Package Insert. Montreal, Quebec; 2002.
70. Omega Laboratories Ltd. Pamidronate Disodium product monograph. Montreal, Quebec; 06 June , 2005.
71. Pfizer Canada-ULC. Pamidronate disodium for injection product monograph. Kirkland, Quebec; December 11, 2018.
72. Sandoz Canada Inc. Pamidronate injection product monograph. Boucherville, Quebec; 28 Februar, 2006.
73. BC Cancer Agency. Pharmacy Policy Number II-20: Guiding Principles for Chemotherapy Preparation Chart. Vancouver, British Columbia: BC Cancer Agency; 19 Septembe , 2007.
74. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 31 Marc, 2017.
75. Amgen Inc. VECTIBIX® full prescribing information. Thousand Oaks, California USA; Jun, 2017.
76. Amgen Canada. VECTIBIX® product monograph. Mississauga, Ontario; 5 March , 2009.
77. Diane Lord. Medical Information Department, Amgen Canada Inc. Personal communication. 19 Jun, 2009.
78. Servier Canada Inc. ONCASPAR® product monograph. Laval, Quebec; November 22, 2021.
79. Merck Canada Inc. KEYTRUDA® product monograph. Kirkland, Quebec; 6 Decembe, 2019.
80. Accord Healthcare Inc. Pemetrexed disodium for injection product monograph. Kirkland, Quebec; 12 Marc, 2015.
81. Accord Healthcare Inc. Pemetrexed solution for injection product monograph. Kirkland, QC; April 26, 2021.
82. Dr. Reddy's Laboratories Limited. Pemetrexed for Injection product monograph . Oakville, Ontario; April 12, 2017.
83. Dr. Reddy's Laboratories Ltd. Pemetrexed for Injection product monograph. Mississauga, Ontario; May 3, 2022.
84. Dr. Reddy's Laboratories Inc. Pemetrexed for injection full prescribing information (package insert). Princeton, NJ, USA; Ma, 2022.
85. Md Aslam. Medical information Associate. Drug information. Dr Reddy's Laboratories. Personal Communication (verbal). December 1, 2022.
86. Eli Lilly and Company. ALIMTA® product monograph. Indianapolis, Indiana, USA; Septembe, 2013.

87. Taro Pharmaceuticals Inc. Pemetrexed disodium for injection product monograph. Brampton, Ontario; 30 Augus, 2018.
88. Hospira Inc. NIPENT® full prescribing information. Lake Forest, Illinois USA; Oc, 2019.
89. Hoffmann-La Roche Limited. PERJETA® product monograph. Mississauga, Ontario; April 12, 2013.
90. Hoffmann-La Roche Limited. PHESGO® product monograph. Mississauga, Ontario; January 5, 2022.
91. sanofi-aventis Canada Inc. MOZOBIL® product monograph. Laval, Quebec; 8 October , 2014.
92. Maureen Coughlin BSc Pharm. Solutions in Health Inc. (acting as an authorized agent of sanofi-aventis and). Personal communication. 24 Ma, 2017.
93. Hoffman-La Roche Limited. POLIVY® product monograph. Mississauga, Ontario; April 27, 2021.
94. Servier Canada Inc. FOLOTYN® product monograph. Laval, Quebec; 19 Octobe, 2018.
95. Marjolaine Migeon PharmD. Servier Canada Medical Information. Personal communication. 24 Septembe, 2019.
96. Pfizer Canada Inc. TOMUDEX® product monograph. Kirkland, Quebec; 8 Augus, 2017.
97. Eli Lilly Canada Inc. CYRAMZA® product monograph. Toronto, Ontario; 16 Jul, 2015.
98. Marilyn Bain BScN. Senior Medical Information Associate, Eli Lilly Canada Inc. Personal communication. 16 Januar, 2017.
99. Hoffmann-La Roche Ltd. RITUXAN® product monograph. Mississauga, Ontario; October 10, 2019.
100. Hoffmann-La Roche Ltd. RITUXAN® SC product monograph. Mississauga, Ontario; March 21, 2018.
101. Sandoz Canada Inc. RIXIMYO® product monograph. Boucherville, Quebec; April 28, 2020.
102. Pfizer Canada-ULC. RUXIENCE® product monograph. Kirkland, Quebec; May 4, 2020.
103. Teva Canada Limited for Celltrion Healthcare Co Ltd. TRUXIMA® product monograph. Toronto, Ontario; July 22, 2019.
104. Celgene Pty Limited. ISTODAX® Australian product information. Mulgrave, Victoria, Australia; February 1, 2022.
105. Gilead Sciences Canada Inc. TRODELVY® product monograph. Mississauga, ON; August 2, 2022.
106. Gilead Medical Information. Gilead Sciences Inc. Personal Communication: Trodelvy® (sacituzumab govitecan) Concentration After Reconstitution. Jan 24, 2022.
107. Recordati Rare Diseases Canada Inc. SYLVANT® product monograph. Toronto, Ontario; July 30, 2024.
108. Recordati Industria Chimica E Farmaceutica (Milan, Italy). Personal Communication: News Release - Recordati completes the acquisition of EUSA Pharma (UK). March 16, 2022.
109. Aadi Bioscience Inc. Pharmacy Manual Protocol PEX-002 (Version 4.0) Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Perivascular Epithelioid Cell Tumors (PEComa) or Patients with Relevant Genetic Mutations for mTOR Pathway Activation. Pacific Palisades, CA, USA; July 16, 2021.
110. Aadi Bioscience Inc. ABI-009 sirolimus albumin-bound nanoparticle (packaging information - BOX). Pacific Palisades, CA; Feb 1 , 2022.
111. Aadi Bioscience Inc. ABI-009 sirolimus albumin-bound nanoparticle (packaging information - VIAL). Pacific Palisades, CA; Feb 1, 2022.
112. Aadi Bioscience Inc. ABI-009 (*nab*-Sirolimus) Investigator's Brochure - version 10.0. Pacific Palisades, CA, USA; July 27, 2021.
113. Keocyt. Streptozocin Keocyt summary of product characteristics, version 5. Montrouge, France; Februar, 2016.
114. Keocyt. ZANOSAR® package leaflet. Montrouge, France; 24 Februar, 2016.
115. Keocyt. ZANOSAR® summary of product characteristics, version 3. Montrouge, France; 31 Octobe, 2017.
116. Keocyt-Riemser Pharma. Marie-Laure Vedel, Sales Order Handling and Hospital Relationship Manager. 16 Septembe, 2021.
117. Amgen Canada Inc. IMDELLTRA® product monograph. Mississauga, Ontario; September 11, 2024.
118. de Lemos, M. BC Cancer Provincial Pharmacy Professional Practice Leader and Drug Information Coordinator. SBAR: Preparing Tarlatamab - BC Cancer Recommendation vs. Product Monograph. BC Cancer - Systemic Therapy Program ; September 12, 2024
119. Medison Pharma Canada Inc.for Immunocore Ireland Limited. KIMMTRAK® product monograph. Toronto, Ontario; June 7, 2022.
120. Pfeiffer, Connie. Head of Medical Affairs Immunocore. Personal Communication. Feb 16, 2022.
121. Janssen Inc. TECVAYLI® product monograph. Toronto, Ontario; July 26, 2023.
122. Janssen Research & Development LLC. Investigational product preparation and Administration instructions for subcutaneous Administration of 10 mg/mL and 90 mg/mL Teclistamab (JNJ-64007957) For Weight-Based Dosing in mcg/kg for Managed Access Programs - Version 6.0 . Beerse, Belgium; June 9, 2023.
123. de Lemos, M. BC Cancer Provincial Pharmacy Professional Practice Leader and Drug Information Coordinator. SBAR: Teclistamab Subcutaneous Injection for Multiple Myeloma at BC Cancer. (draft). BC Cancer - Systemic Therapy Program ; September 1, 2023
124. Pfizer Canada Inc (for Wyeth Canada). TORISEL® product monograph. Kirkland, Quebec; 21 December , 2016.
125. Anna Sivojelezova M.Sc. Medical Information Associate, Wyeth. Personal communication. 6 Januar, 2010.
126. Bristol-Myers Squibb Canada. VUMON® product monograph. St. Laurent, Quebec; 26 October , 2004.
127. Trissel's®2 IV Compatibility (database on the Internet). Teniposide. Thomson Reuters MICROMEDEX® 2.0; Accessed 27 Apri, 2011. Available at: http://www.micromedex.com

128. Hikma Canada Limited. Thiotepa for injection product monograph. Mississauga, Ontario; March 14, 2023.
129. AHFS DI® (Adult and Pediatric) (database on the Internet). Thiotepa. UpToDate® Lexidrug®; Accessed October 16, 2023. Updated March 11, 2023. Available at: http://online.lexi.com
130. BC Cancer Miscellaneous Origin Tumour Group. (MOIT) BC Cancer Protocol Summary for Solid Tumours using Intrathecal Methotrexate and/or Thiotepa and/or Cytarabine. Vancouver, British Columbia: BC Cancer; September 1 , 2021.
131. BC Cancer. Systemic Therapy Policy and Procedure III-50: Administration of High Alert Medications by the Intrathecal Route via Lumbar Puncture or Ommaya Reservoir. Vancouver, British Columbia; December 29, 2022.
132. SteriMax Inc. Thiotepa for injection product monograph. Oakville, Ontario; April 5, 2023.
133. Sanofi Genzyme. THYROGEN® product monograph. Mississauga, Ontario; July 29, 2021.
134. BeiGene Ireland Ltd. TEVIMBRA® Summary of product characteristics. Dublin, Ireland; Januar, 2023.
135. Hoffmann-La Roche Limited. ACTEMRA® product monograph. Mississauga, Ontario; 27 Octobe, 2017.
136. Accord Healthcare Inc. Topotecan hydrochloride for injection product monograph. Kirkland, Quebec; May 9, 2019.
137. BC Children's Hospital (Distribution - Sterile Compounding). Iintrathecal or Intra-OMAYA Compounding Worksheet: Topotecan IT or Intra-Ommaya Syringe. Vancouver, British Columbia; May, 2020.
138. Poplack Potter SL, Berg S, Ingle AM, et al. Phase 2 clinical trial of intrathecal topotecan in children with refractory leptomeningeal leukemia: a Children's Oncology Group trial (P9962). Pediatr Blood Cancer ; 2012;58(3):362–365
139. Pfizer Canada Inc. Topotecan hydrochloride for injection product monograph. Kirkland, Quebec; April 9, 2021.
140. Sandoz Canada Inc. Topotecan injection product monograph. Boucherville, Quebec; March 29, 2019.
141. Hoffmann-La Roche Limited. HERCEPTIN® product monograph. Mississauga, Ontario; May 7, 2020.
142. Celltrion Healthcare Co Ltd (distributed by Teva Canada Limited). HERZUMA® product monograph. Toronto, Ontario; 20 Octobe, 2020.
143. BGP Pharmacy ULC. OGIVRI® product monograph. Etobicoke, Ontario; 3 Ma, 2019.
144. Pfizer Canada-ULC. TRAZIMERA® product monograph. Kirkland, Quebec; August 15, 2019.
145. AstraZeneca Canada Inc. ENHERTU® product monograph. Mississauga, Ontario; 15 Apri, 2021.
146. AstraZeneca Canada Inc. Medical Information. 5 Octobe, 2021.
147. Hoffmann-La Roche Limited. KADCYLA® product monograph. Mississauga, Ontario; 11 Septembe, 2013.
148. Hoffmann-La Roche Limited. KADCYLA® product monograph. Mississauga, Ontario; July 3, 2020.
149. AstraZeneca Canada Inc. IMJUDO® product monograph. Mississauga, Ontario; January 26, 2024.
150. Medexus Inc. TRECONDYV® product monograph. Bolton, Ontario; June 25, 2021.
151. Erin Wallace. Ontario Territory Manager, Medexus Pharmaceuticals Inc. Personal Communication - TRECONDYV®. November 2, 2021.
152. Medical Information team. Medexus Pharmaceuticals Inc. Personal Communication - TRECONDYV®. November 1, 2021.
153. medac GmbH. TRECONDI® summary of product characteristics. Wedel, Germany;
154. medac-UK. TREOSULFAN injection® summary of product characteristics. Wedel, Germany; 26 Ja, 2017.
155. medac-UK. TREOSULFAN injection® Details about Handling and Stability. Hamburg, Germany; Augus, 2008.
156. Henrik Fenger. Management Associate, International Division medac. Personal communication. 03 Marc, 2010.
157. medac-UK. TREOSULFAN injection® summary of product characteristics. Hamburg, Germany; 24 Ju, 2008.
158. Pfizer Canada-ULC. Vinblastine sulfate injection product monograph. Kirkland, Quebec; April 18, 2019.
159. Lexi-Drugs® (database on the Internet). VinBLAStine. Lexi-Comp Inc.; Accessed 30 Januar, 2020. Available at: http://online.lexi.com
160. BC Cancer Provincial Systemic Therapy Program. Policy V-40: Dispensing and Labelling of Vinca Alkaloid Preparations. Vancouver, British Columbia: BC Cancer; 1 Apri , 2015.
161. World Health Organization. Information Exchange System - Vincristine (and other vinca alkaloids) should only be given intravenously via a minibag. Alert No. 115 ed. Geneva, Switzerland: World Health Organization; 18 Jul , 2007.
162. Teva Canada Limited. Vinblastine sulfate injection product monograph. Toronto, Ontario; 22 Octobe, 2019.
163. Pfizer Canada-ULC. Vincristine sulfate injection product monograph. Kirkland, Québec; July 26, 2021.
164. Teva Canada Limited. Vincristine sulfate injection® product monograph. Scarborough, Ontario; March 27, 2014.
165. Pharmaceutical Partners of Canada. Vinorelbine Injection product monograph. Richmond Hill, Ontario; 15 January , 2008.
166. Generic Medical Partners Inc. Vinorelbine Injection product monograph. Toronto, Ontario; 3 Septembe, 2014.
167. Teva Canada Limited. Vinorelbine tartrate for Injection product monograph. Toronto, Ontario; 20 Marc, 2014.

168. Innomar Strategies Inc. (for Dr. Reddy's Laboratories Limited). Zoledronic acid for injection concentrate® product monograph. Oakville, Ontario; 11 Marc, 2015.
169. Marcan Pharmaceuticals Inc. Zoledronic acid concentrate for injection product monograph. Ottawa, Ontario; 5 Februar, 2018.
170. MDA Inc. Zoledronic acid for injection product monograph. Mississauga, Ontario; 11 Augus, 2015.
171. Novartis Pharmaceuticals Canada Inc. ZOMETA® product monograph. Dorval, Quebec; 26 Jul, 2013.
172. Sandoz Canada Inc. Zoledronic Acid - Z® product monograph. Boucherville, Quebec; 02 Decembe, 2016.
173. The United States Pharmacopeia (. General Chapter 797: Pharmaceutical compounding - sterile preparations. USP 27-NF 22. Rockville, Maryland: The United States Pharmacopeial Convention, Inc.; 2004.
174. Kastango ES. The ASHP discussion guide for compounding sterile preparations. Bethesda (MD): American Society of Health-System Pharmacists, Inc.; 2004. p. 5